We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

183 hedge funds and large institutions have $1.39B invested in KalVista Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 63 increasing their positions, 45 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 16

84% more call options, than puts

Call options by funds: $39.1M | Put options by funds: $21.2M

80% more funds holding in top 10

Funds holding in top 10: 5 → 9 (+4)

40% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 45

29% more capital invested

Capital invested by funds: $1.08B → $1.39B (+$313M)

14% more funds holding

Funds holding: 161 → 183 (+22)

2.77% more ownership

Funds ownership: 132.43% → 135.2% (+2.8%)

Holders
183
Holders Change
+22
Holders Change %
+13.66%
% of All Funds
2.25%
Holding in Top 10
9
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+80%
% of All Funds
0.11%
New
41
Increased
63
Reduced
45
Closed
16
Calls
$39.1M
Puts
$21.2M
Net Calls
+$17.9M
Net Calls Change
+$11.5M

Top Buyers

Rank Fund Capital Flow
1
DCM
Driehaus Capital Management
Illinois
+$9.09M
2
SSC
Spruce Street Capital
New York
+$8.22M
3
SCM
Silverarc Capital Management
Massachusetts
+$7.24M
4
AC
Armistice Capital
New York
+$7.03M
5
CCM
Catalio Capital Management
New York
+$6.87M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$15.9M
2
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
-$10.7M
3
WP
Woodline Partners
California
-$6.63M
4
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB)
Sweden
-$5.68M
5
O
OrbiMed
New York
-$4.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
51
Fidelity Investments
Massachusetts
$3.78M +$1.23M +76,041 +68%
Qube Research & Technologies (QRT)
52
Qube Research & Technologies (QRT)
United Kingdom
$3.63M +$2.91M +180,314 New
ECM
53
ExodusPoint Capital Management
New York
$3.57M +$2.53M +157,213 +784%
Marshall Wace
54
Marshall Wace
United Kingdom
$3.28M +$2.63M +162,908 New
NFT
55
Nan Fung Trinity
Hong Kong
$3.11M – – –
Two Sigma Investments
56
Two Sigma Investments
New York
$3.09M +$2.47M +153,459 New
Squarepoint
57
Squarepoint
New York
$2.9M +$2.32M +143,966 New
Raymond James Financial
58
Raymond James Financial
Florida
$2.83M +$179K +11,134 +9%
TI
59
Trexquant Investment
Connecticut
$2.81M +$2.25M +139,458 New
NCM
60
NEXTBio Capital Management
California
$2.65M – – –
SFCM
61
Seven Fleet Capital Management
California
$2.59M +$1.29M +80,075 +165%
BHCM
62
Brevan Howard Capital Management
Jersey
$2.42M +$1.06M +65,902 +111%
Wellington Management Group
63
Wellington Management Group
Massachusetts
$2.16M -$244K -15,117 -12%
N
64
Nuveen
North Carolina
$2.15M -$4.27K -265 -0.2%
Citadel Advisors
65
Citadel Advisors
Florida
$1.97M +$966K +59,965 +159%
O
66
OrbiMed
New York
$1.9M -$4.64M -288,000 -75%
Walleye Capital
67
Walleye Capital
New York
$1.6M +$1.28M +79,666 New
XT
68
XTX Topco
Cayman Islands
$1.59M +$848K +52,610 +198%
Invesco
69
Invesco
Georgia
$1.52M -$41.6K -2,582 -3%
MAM
70
Martingale Asset Management
Massachusetts
$1.41M +$629K +39,006 +126%
SLAM
71
Swiss Life Asset Management
$1.38M +$353K +21,885 New
CCIA
72
Campbell & Co Investment Adviser
Maryland
$1.29M +$1.04M +64,249 New
Creative Planning
73
Creative Planning
Kansas
$1.21M +$256K +15,904 +36%
Rafferty Asset Management
74
Rafferty Asset Management
New York
$1.15M -$134K -8,297 -13%
BC
75
Birchview Capital
Vermont
$1.15M – – –
1 2
3
4 5

KALV Hedge Fund Activity: Q1 2026 in Review

183 of the 8,133 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2026, worth a combined $1.39B — up 29% from $1.08B a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new KALV positions and 16 closed out — a net gain of 25 holders — while 63 added to existing stakes and 45 trimmed.

The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $9.09M. The largest seller was Millennium Management, cutting an estimated $15.9M.

  • 183 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2026, up from 161 in Q4 2025.
  • Funds reported $1.39B of KalVista Pharmaceuticals stock for Q1 2026, up 29% quarter-over-quarter.
  • 41 funds opened new KalVista Pharmaceuticals positions in Q1 2026 and 16 closed out, a net change of +25 holders.
  • The largest KalVista Pharmaceuticals buyer in Q1 2026 was Driehaus Capital Management, an estimated $9.09M added.
  • The largest KalVista Pharmaceuticals seller in Q1 2026 was Millennium Management, an estimated $15.9M sold.

Based on aggregated 13F filings for Q1 2026.